Cytokines including IL-6 and TNF-a play an important role in the pathogenesis of postmenopausal osteoporosis. However, the relationship between changes in the cytokine levels and subsequent bone loss in patients undergoing a bone marrow transplantation (BMT) is unclear. A total of 46 patients undergoing an allogeneic BMT were prospectively investigated. The bone turnover markers and the serum cytokines were measured before BMT and serially after BMT. Bone mineral density (BMD) was measured before and 1 year after BMT. At 1 year after BMT, the lumbar spine BMD had decreased by 4.8%, and the total proximal femoral BMD had decreased by 12.3%. The serum IL-6 and TNF-a levels increased until 2 and 3 weeks after BMT, respectively. The lumbar BMD was significantly decreased as the serum IL-6 and TNF-a levels increased by post-BMT 3 weeks. The lumbar BMD decreased significantly as the cumulative prednisolone and cyclosporine dose increased. Patients with GVHD Xgrade II had higher lumbar bone loss than patients with GVHD ograde I. In conclusion, immunosuppressants, GVHD occurrence and increase in bone-resorbing cytokines in the early post-BMT period were associated with later bone loss after BMT. Further studies are needed to elucidate the precise mechanism. Bone marrow transplantation (BMT) is an established method for treating various hematological diseases. As the number of long-term survivors increased due to the improved prognosis after BMT, the number of endocrine complications has also increased. Endocrine complications brought about after a BMT include hypogonadism, thyroid dysfunction, hypopituitarism, diabetes and osteoporosis. A significant bone loss occurs during the first year after a BMT with up to a 5-10% decrease in the bone mineral density (BMD) in the lumbar spine and proximal femur. The post-BMT bone loss is mainly related to the immunosuppressants and the gonadal dysfunctions secondary to myeloablative therapy and/or total body irradiation (TBI).
Bone marrow transplantation (BMT) is an established method for treating various hematological diseases. As the number of long-term survivors increased due to the improved prognosis after BMT, the number of endocrine complications has also increased. Endocrine complications brought about after a BMT include hypogonadism, thyroid dysfunction, hypopituitarism, diabetes and osteoporosis. A significant bone loss occurs during the first year after a BMT with up to a 5-10% decrease in the bone mineral density (BMD) in the lumbar spine and proximal femur. The post-BMT bone loss is mainly related to the immunosuppressants and the gonadal dysfunctions secondary to myeloablative therapy and/or total body irradiation (TBI). [1] [2] [3] [4] [5] The rapid impairment in bone formation and the increase in bone resorption, as mirrored by the biochemical markers, might play a role in bone loss, particularly during the early post-BMT period. 1 The pathogenic role of the cytokines is well known in the development of postmenopausal osteoporosis and other forms of secondary osteoporosis. Interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a) are known to increase bone resorption by stimulating osteoclasts. 6 However, there are few reports on the relationship between changes in the bone metabolism and cytokine levels after a BMT. 7, 8 In particular, there is no report on the effects of the drastically changing cytokine levels in the early post-BMT period on the long-term changes in the BMD after a BMT. It was previously reported that the bone marrow plasma IL-6 level, which reflects the real changes in the bone marrow microenvironment, was significantly related to the serum bone resorption markers after a BMT. 8 This study measured the serum IL-6, TNF-a and bone turnover marker levels serially before and after a BMT in 46 patients undergoing a BMT. The BMD was measured before BMT and 1 year after BMT in 22 out of 46 patients. In addition, this study observed the effect of increased cytokine levels in the early post-BMT period on the subsequent bone loss during the first year after a BMT.
Subjects and methods

Subjects
A total of 205 patients with various hematological diseases received a BMT between October 1998 and August 1999 at St Mary's Hospital in Seoul, Korea. All autologous BMTs were excluded from this group and 46 patients (28 male and 18 female patients) undergoing an allogeneic BMT were prospectively investigated. All patients provided informed consent to this study. The mean age of these patients was 3277.9 years. The underlying hematological diseases were leukemia in 41 patients, severe aplastic anemia in three and myelodysplastic syndrome in two.
The pretreatment prior to BMT involved TBI in 24 patients (52%). Fractionated irradiation was achieved by giving a total of 10-13.2 Gy radiation over 4-5 days. A high dose of cyclophosphamide (60 mg/kg/day) was given for 2-4 days as a pretreatment in 38 patients (82.6%). In order to prevent graft-versus-host diseases (GVHD), intravenous cyclosporin A 5 mg/kg/day was administered to the allogeneic BMT recipients 1 day before BMT and 3 mg/ kg/day thereafter until the 20th day. Subsequently, oral cyclosporine A at 6 mg/kg/day was begun, which was continued in a tapering dose for 6-12 months. The established GVHD was treated with a combination of intravenous methylprednisolone or oral prednisolone and cyclosporine A. The doses were tapered when the clinical control of the GVHD was achieved. GVHD was based on clinical signs and graded on a four-point scale (I indicated mild disease and IV severe disease). Among the 46 subject patients, only 22 patients were followed up for 1 year after BMT because seven patients had died and the others were not followed up due to recurrence, being transferred to other hospitals or refusing to undergo tests.
Biochemical markers and cytokines
Blood was sampled in order to determine the serum levels of calcium, phosphorus, creatinine, total alkaline phosphatase (747 Automatic analyzer, Hitachi, Japan), osteocalcin and ICTP before BMT, and at 1, 2, 3, 4, 12 weeks, 6 months and 1 year after BMT. The serum cytokine (IL-6, TNF-a) levels were measured before BMT, and at 1, 2, 3, 4 weeks and 3 months after BMT. The blood samples were taken between 0700 and 0900 following an overnight fast, in order to measure the biochemical markers. The serum creatinine levels were determined using an autoanalyzer (747 Automatic analyzer, Hitachi, Japan). The serum osteocalcin (Ntact s osteo SP, Incstar, USA) and ICTP (Telopeptide ICTP, Orion Diagnostica, Finland) levels were determined by a radioimmunoassay. The maximum inter-and intraassay coefficients of variation in the range of concentrations evaluated were 7.7 and 5.4% for osteocalcin, and 10.7 and 3.6% for ICTP, respectively. The IL-6 and TNF-a (ELISA kit, Hyundae Pharm. Research Institute, Korea) concentrations were measured in duplicate by enzyme-linked immunosorbent assays with detection limits of 4 and 7 pg/ml, respectively. The maximum inter-and intra-assay coefficients of variation (CVs) for the range of concentrations evaluated were 8.3 and 6.2% for IL-6, and 8.2 and 7.0% for TNF-a, respectively.
Bone densitometry
The BMD of the lumbar spine (lumbar vertebrae L 2 -L 4 ) and of the proximal femur (femoral neck, trochanter, Ward's triangle) was measured by dual-energy X-ray absorptiometry (DEXA) using a Lunar Expert (Lunar, Madison, WI, USA) before BMT and 12 months after BMT. The precision of the method (CV) was 1.0% at both locations.
Statistical analysis
All values are reported as a mean7s.e.m. Statistical analysis was performed using SPSS software. The comparisons between the pre-BMT and post-BMT biochemical characteristics were undertaken using a Student's t-test for the paired data. The Pearson's correlation coefficients were used to examine the bivariate correlations between the two variables. A P-value o0.05 was considered significant.
Results
Changes in BMD
Among the 46 patients, the BMD was measured before BMT and 1 year after BMT in 22 patients. The average lumbar BMD was 1.15970.042 g/cm 2 before BMT and 1.10470.047 g/cm 2 
Changes in bone turnover markers
The level of the bone resorption marker, ICTP, progressively increased up to 4 weeks after BMT, and then recovered to the pre-BMT level 1 year after BMT. The level of the bone formation marker, osteocalcin, decreased progressively and reached its nadir 3 weeks after BMT. Thereafter, it recovered to the baseline level by 12 months (Figure 2 ). 12.3% * Figure 1 Changes in the BMD before and after a BMT. The mean bone loss in the lumbar spine, calculated as the percentage change from the baseline to the level at 12 months after BMT, was 4.8%. In the proximal femur, the amount of bone loss was calculated to be 12.3% from the baseline to the level 12 months after BMT (*Po0.01).
Changes in serum cytokines
The serum IL-6 level increased until 2 weeks after BMT (226.4764.8 pg/ml, Po0.05 vs baseline) and declined thereafter. The serum TNF-a increased until 3 weeks after BMT (146.6735.6 pg/ml, Po0.01 vs baseline) and declined thereafter ( Figure 3) .
Relationship between the serum cytokine levels and the loss of BMD
The relationship between the cytokine (IL-6, TNF-a) levels and changes in the BMD (lumbar and proximal femur) was examined. The lumbar BMD was significantly decreased as the serum IL-6 (correlation coefficient: À0.22, Po0.05) and TNF-a levels increased by post-BMT 3 weeks (correlation coefficient: À0.42, Po0.05). However, the relationships between the serum IL-6 level and changes in the proximal femoral BMD and between the serum TNF-a and changes in the proximal femoral BMD were not significant.
Relationship between steroid dose and the loss of BMD
The mean cumulative dose of prednisolone administered 1 year after the BMT was 4.771.2 g. When the relationship between the cumulative prednisolone dose and changes in the BMD from the baseline lumbar was examined, the lumbar BMD decreased as the cumulative prednisolone dose increased (correlation coefficient: À0.63, Po0.01), but the relationship between cumulative prednisolone dose and femoral bone change was not significant.
The high-dose steroid group was arbitrarily defined as those patients receiving a cumulative prednisolone dose of above 2 g during 1 year after BMT. The mean cumulative dose of prednisolone administered during the post-BMT 1 year was 6.872.2 and 0.970.5 g in high-dose steroid group (n ¼ 11) and the low-dose steroid group (n ¼ 11), respectively. Patients with high steroid dose had greater bone loss in lumbar spine than those with low steroid dose. However, the femoral bone loss was not significantly different according to the steroid dose ( Figure 4 ).
Relationship between cyclosporine dose and the loss of BMD
The mean cumulative dose of cyclosporine administered 1 year after BMT was 68.1718.4 g. When the relationship between the cumulative cyclosporine dose and changes in the BMD from the baseline lumbar was examined, the lumbar BMD decreased as the cumulative cyclosporine dose increased (correlation coefficient: À0.54, Po0.05), but the relationship between cumulative cyclosporine dose and femoral bone loss was not significant. against the basal value. After BMT, the level of ICTP, a marker of bone resorption, progressively increased, reaching its peak at 4 weeks. Thereafter, it declined to the baseline at 12 months. The osteocalcin level, which is a marker of bone formation, decreased reaching its nadir at 3 weeks. Thereafter, it recovered to the baseline level by 12 months. The serum creatinine levels were within the normal range throughout the entire observation period. Figure 3 Changes in the serum cytokine levels, before and after the allogeneic BMT. The data are reported as a mean value (7s.e.m.). *Po0.05, wPo0.01 against the basal value. Following BMT, the serum IL-6 levels increased reaching a peak at 2 weeks and declining thereafter.
The serum TNF-a levels increased reaching a peak at 3 weeks and also declining thereafter.
The high-dose cyclosporine group was arbitrarily defined as those patients receiving a cumulative cyclosporine dose of above 60 g during 1 year after BMT. The mean cumulative dose of cyclosporine administered during the post-BMT 1 year was 79.3716.2 and 52.076.8 g in highdose cyclosporine group (n ¼ 11) and the low-dose cyclosporine group (n ¼ 11), respectively. Patients with high cyclosporine dose had greater bone loss in lumbar spine than those with low cyclosporine dose. However, the femoral bone loss was not significantly different according to the cyclosporine dose ( Figure 5 ).
Relationship between GVHD and the loss of BMD
Out of 22 patients who were followed up until 1 year after BMT, 14 patients had GVHD. Acute GVHD occurred in three patients, chronic GVHD in seven patients and both in four patients. The grade of GVHD was as follows: I (n ¼ 5), II (n ¼ 7), III (n ¼ 1), IV (n ¼ 1). Patients with GVHD Xgrade II (n ¼ 9) had greater bone loss in lumbar spine than those with GVHD ograde I (n ¼ 13). However, the femoral bone loss was not significantly different according to the severity of GVHD ( Figure 6 ).
Discussion
Many patients worldwide undergo organ transplants each year, and this figure is expected to increase as advances in surgical techniques and immunosuppressive therapy make transplantation more successful. Therefore, patients are living longer, although a new set of side effects, such as diabetes mellitus, thyroid disease, hypogonadism, hypopituitarism, growth retardation, adrenal insufficiency, etc., which are unique to these groups of patients, has been recognized. Osteoporosis has also been well documented as a complication of renal, hepatic and cardiac transplants. Unlike solid organ transplants, patients undergoing a BMT are generally younger and the time elapsing from the diagnosis to BMT is relatively short. Despite these factors, bone loss is frequently observed after a BMT. It was previously reported that bone disease is one of the complications of a BMT. 1, 5 According to Castaneda et al, 33 and 18% of BMT recipients had osteopenia and osteoporosis in the lumbar spine when examined 33.6 months after BMT. The main causes of bone loss following a BMT include the use of immunosuppressants and hypogonadism induced by TBI or chemotherapy. It is well known that IL-1, IL-6 and TNF-a play an important role in the pathogenesis of postmenopausal osteoporosis. These cytokines induce differentiation of osteoclast precursors into mature osteoclasts, consequently increasing the amount of bone resorption. 10 However, the relationship between the cytokine levels and the post-BMT bone loss is not well known and, to our knowledge, a prospective study on changes in the cytokines in accordance with the BMD has not been performed. Drastic changes in the cytokine levels also occur during the early post-BMT period. 11, 12 In a previous study, it was also reported that the progressive increase of bone resorption during the early post-BMT period is related to an increase in the bone marrow IL-6 levels, which is a potent stimulator of bone resorption in vivo. The previous study was extended with the intention of examining whether or not the early changes in cytokine levels could affect the later bone loss following BMT. This study demonstrated that an increase in IL-6 and TNF-a levels during the early post-BMT period was related to the decreased lumbar BMD. 8 Withold et al 7 reported that there was a correlation between the increased bone resorption markers and the increased peripheral blood IL-6 levels after BMT. The above findings suggest that the changes in the bone-resorbing cytokines are possible causes for the post-BMT bone loss. A previous study found that most of the women went into a menopausal state immediately after a BMT. 1 The high gonadotropin and low estradiol levels were evidence for this. In contrast, the gonadotropin and testosterone levels did not change significantly in the male patients after the BMT, suggesting that hypogonadism was not induced in men. 1, 4 However, the possibility that drastic changes in cytokine levels in the early stages after a BMT could be solely induced by hypogonadism appears to be low. Although there is a large body of evidence suggesting that the decline in the ovarian function is associated with the spontaneous increase in the proinflammatory cytokines, efforts to demonstrate that the cytokine increases are related to the estrogen deficiency in tissue samples in vivo 13, 14 or in circulation [15] [16] [17] [18] have been less successful. Increases in the IL-6 and TNF-a levels with an estrogen deficiency are subtle compared with the increases observed as a host reaction to an infection or a major tissue injury. 19 It is generally known that after a BMT, the levels of circulating IL-6 and TNF-a increase during the aplastic phase in most patients and is associated with several complications, such as GVHD or infectious episodes. 20 IL-6 is produced by almost all cells including hepatocytes, and is involved in many aspects of the inflammatory response. 21 Therefore, it is not unusual to find higher IL-6 levels in human pathological conditions. IL-6 stimulates the early stages of hematopoiesis, as well as the early stages of osteoclastogenesis. 21 TNF-a stimulates the osteoblasts to secrete other cytokines (IL-1 and IL-6) and prostaglandin E 2 as well as TNF-a itself, which act directly on the osteoclasts to cause bone resorption. 22, 23 In BMT setting, IL-6 is known to be the most important cytokine during the initial inflammatory response and correlates significantly with the TNF-a level. 24 Therefore, the development of an osteoclast lineage following a BMT may be supported by these bone-resorbing cytokines.
It should be noted that site-selective differences between the lumbar spine and femoral BMD change are observed. The exact mechanisms for this site selectivity need to be elucidated. However, it may be partly due to the differences in the tissue expression of several proteins related to bone metabolism including certain growth factors and BMP-2 according to the skeletal site. 25, 26 The BMD response in postmenopausal women to therapeutic agents (eg bisphosphonate and hormone replacement therapy) is also different in lumbar and femoral bones, but the exact mechanism is unknown. [27] [28] [29] This study also could not observe a significant correlation between the cytokines and proximal femoral bone loss, possibly because the effects of the cytokines on bone are different according to the skeletal sites. The exact mechanism should be elucidated by further studies.
There are possible causes for the inhibition of osteoblast function, as shown by the decrease in the osteocalcin level during the few weeks following a BMT. One explanation is that a substantial number of osteoprogenitor cells are directly damaged by the myeloablative therapy. 30 The administration of steroids to treat GVHD and GVHD itself may be another possible explanation for the decreased osteoblastic activity following a BMT. 9 A previous study observed a negative correlation between the serum osteocalcin level and the mean daily dose of steroids that were administered during the 3 months after a BMT. 8 This study also observed a significant correlation between the cumulative steroid dose and bone loss in the lumbar and proximal femoral bones during the first year after a BMT. It is well recognized that steroids have deleterious effects on the bone mineral metabolism. 31 Trabecular bone loss can result from a prednisolone dose as low as 7.5 mg/day. In this study, the mean cumulative dose of prednisolone administered during the first year after a BMT was 4.7 g. This is equivalent to a mean daily dose of 12.9 mg, which is sufficient to inhibit osteoblast activity. GVHD severity was also significantly associated with lumbar bone loss in this study. It is compatible to the previous studies.
1,2 It might be due to a direct effect of GVHD itself on bone cells and treatment for GVHD.
Cyclosporine might also be another factor that can affect bone metabolism. It is known to produce a large amount of bone remodeling with the amount of bone resorption exceeding bone formation and can therefore induce osteopenia when used in immunosuppressive doses. 32 We found significant relationship between cumulative cyclosporine dose and lumbar bone loss. It was interesting that cyclosporine dose was not significantly related to femoral bone loss, displaying again the site-selective differences in bone loss in response to drug.
Appropriate drugs could be helpful for preventing post-BMT osteoporosis (eg bisphosphonates). However, more convincing data are required to use cytokine levels as a predictive parameter to determine patients who are in need of drug therapy.
This study has several limitations. First, we did not measure bone density at an earlier time point after BMT such as post-BMT 6 months. It would have been of value to do bone density studies at an earlier time point to see if there are changes directly associated with cytokines that might be reversible. Second, it was difficult to evaluate the independent effect of serum cytokine levels on bone loss, because so many factors contributed to bone loss. Third, many patients were not followed up in this prospective study. We think that more patients are needed to elucidate the real mechanism of post-BMT bone loss in future studies.
In conclusion, immunosuppressants, GVHD occurrence and increase in bone-resorbing cytokines in the early post-BMT period were associated with later bone loss after BMT. Further studies are needed to elucidate the precise mechanism of these relations.
